The effect of combination therapy on Bevacizumab, Carmustine, and Metformin chemotherapy drugs on the fluctuating performance expression of TLR2, TLR6, and IL-6 genes in the cell line of brain glioblastoma
The combination of bevacizumab, carmustine, and metformin exerts a potent synergistic antitumor effect in U87MG glioblastoma cells through modulation of inflammation-associated genes, induction of apoptosis, and disruption of cell cycle progression. These findings provide a mechanistic rationale for multi-targeted combination therapy in glioblastoma and support further preclinical evaluation.
Authors
- Seyedeh Elham Norollahi (ORCID: https://orcid.org/0000-0002-4065-9112)
- Ebrahim Mirzajani (ORCID: https://orcid.org/0000-0002-9382-1822)
- Mohamad Eftekhary (ORCID: https://orcid.org/0000-0002-1266-6868)
- Fatemeh Nejatifar (ORCID: https://orcid.org/0000-0002-3858-8482)
- Masoud Faghih Akhlaghi (ORCID: https://orcid.org/0000-0003-2949-2814)
- Bahman Yousefi (ORCID: https://orcid.org/0000-0002-4220-1527)
- Ali Rashidy‐Pour (ORCID: https://orcid.org/0000-0001-5006-1408)
- Mohammad Samadian (ORCID: https://orcid.org/0000-0002-4212-1738)
- Mehdi Evazalipour (ORCID: https://orcid.org/0000-0002-5518-0024)
- Ali Akbar Samadani
- Shahrokh Yousefzadeh-Chabok (ORCID: https://orcid.org/0000-0002-7780-1565)
Institutions
- Guilan University of Medical Sciences (IR)
- Biotechnology Research Center (IR)
- Semnan University of Medical Sciences (IR)
- Razi Hospital (IR)
- Shahid Beheshti University of Medical Sciences (IR)
- University of Guilan (IR)
Publication Details
- Journal
- Cancer Cell International
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1186/s12935-025-04033-0
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00